Sight Sciences, Inc. provided revenue guidance for the Fourth quarter and Full year 2023. For the quarter, the company's total revenue is expected to be in the range of $18.6 million to $18.8 million, a decrease of 9% compared to the prior year period at the estimated midpoint. Surgical Glaucoma revenues are expected to be in the range of $17.1 million to $17.2 million, a decrease of 9% compared to the prior year period at the estimated midpoint. Dry Eye revenues are expected to be in the range of $1.5 million to $1.6 million, a decrease of 13% compared to the prior year period at the estimated midpoint.

For the year, the company's total revenue is expected to be in the range of $80.9 million to $81.1 million, an increase of 14% compared to the prior year at the estimated midpoint. Surgical Glaucoma revenues are expected to be in the range of $74.3 million to $74.4 million, an increase of 13% compared to the prior year at the estimated midpoint. Dry Eye revenues are expected to be in the range of $6.6 million to $6.7 million, an increase of 17% compared to the prior year at the estimated midpoint.